Source:http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/3478
Predicate | Object |
---|---|
rdf:type | |
rdfs:label |
Reno-30 (Injection, Solution)
|
dailymed-instance:dosage |
Preparation of the patient: Appropriate
preparation is desirable for optimal
results. A laxative the night before the
examination and a low residue diet the
day before the procedure are
recommended. Dosage: The usual dose for patients
aged 16 years or more is 15 mL for
unilateral and appropriately increased
volumes for bilateral pyelograms.
Approximately 5 to 6 mL will generally
be required for each exposure. The
dosage for children should be
proportionately smaller than the adult
dose. As supplied, the preparation provides
maximum opacification. If a lesser
contrast is desired, it may be diluted
with sterile distilled water. Administration: Reno-30 may be
introduced by a gravity flow system or
by syringe. When the syringe method is
used, the injections should be made
slowly and care should be exercised to
use as little manual pressure as
possible. Regardless of the system
used, injection of the contrast medium
should be terminated as soon as the
patient complains of a sense of fullness
or pain in the renal region. Radiography: The commonly employed
radiographic techniques should be
used. A scout film is recommended
before the contrast agent is
administered.
|
dailymed-instance:descripti... |
Reno-30 is a radiopaque contrast agent
for retrograde pyelography supplied as
a sterile, aqueous solution. Each mL
provides 300 mg diatrizoate meglumine
with 3.2 mg sodium citrate as a buffer,
0.4 mg edetate disodium as a
sequestering agent, and 1 mg
methylparaben and 0.3 mg
propylparaben as preservatives. Each
mL of solution also contains
approximately 141 mg organically
bound iodine. At the time of
manufacture, the air in the container is
replaced by nitrogen.
|
dailymed-instance:activeIng... | |
dailymed-instance:contraind... |
Reno-30 is contraindicated for use in
intrathecal procedures. Contraindications pertain to the
procedure of retrograde pyelography
rather than to the administration of the
medium per se. Retrograde pyelography
should not be performed in those
conditions which do not allow for the
successful catheterization of the ureters
such as extensive urinary tuberculosis,
tumors of the bladder, impassable
obstructions of the ureters, or marked
enlargement of the prostate gland.
|
dailymed-instance:supply |
Reno-30 (Diatrizoate Meglumine
Injection USP 30%) is available in
packages of: Twenty-five 50 mL multiple
dose vials (NDC 0270-0804-45).<br/>Storage: The preparation should be protected
from strong light and stored at 20���25��C
(68���77��F) [See USP]; avoid freezing.
|
dailymed-instance:boxedWarn... |
NOT FOR INTRATHECAL USE
|
dailymed-instance:activeMoi... | |
dailymed-instance:inactiveI... | |
dailymed-instance:precautio... |
Because of the possibility of inducing
temporary suppression of urine, it is
wise to avoid repetition of retrograde
pyelography within 48 hours in patients
with reduced renal function. Retrograde pyelography should be
performed with caution in patients with
a known active infectious process of the
urinary tract. Contrast agents may interfere with
some chemical determinations made on
urine specimens; therefore, urine
should be collected before
administration of the contrast medium
or two or more days afterwards.
|
dailymed-instance:genericMe... |
diatrizoate meglumine
|
dailymed-instance:fullName |
Reno-30 (Injection, Solution)
|
dailymed-instance:adverseRe... |
The incidence of adverse reactions with
diatrizoate meglumine is very low.
Costovertebral angle tenderness,
elevated temperature and flank pain
have been reported in a few patients
following use of the preparation for
retrograde pyelography, as have nausea,
sweating and flushing. Irritation of the urinary tract mucosa
attributable to the contrast agent itself
is not likely to occur. However, the
technique of retrograde pyelography
may be painful and may initiate pelvic,
caliceal, or ureteral spasms with
consequent renal colic. Since retrograde pyelography does not
involve systemic administration of a
contrast agent, the risk of severe
reactions, which may occur with
intravenous administration, is extremely
remote. However, they should be kept in
mind whenever a contrast agent is
administered. Severe reactions may be
manifested by edema of the face and
glottis, respiratory distress,
convulsions, or shock; such reactions
may prove fatal unless promptly
controlled by such emergency
measures as maintenance of a clear
airway and immediate use of oxygen
and resuscitative drugs. Like other
sensitivity phenomena, severe reactions
are more likely to occur in patients with
a personal or family history of bronchial
asthma, significant allergies, drug
reactions, or previous reactions to
contrast agents.
|
dailymed-instance:warning |
Severe Adverse Events���Inadvertent
Intrathecal Administration: Serious adverse reactions have been
reported due to the inadvertent
intrathecal administration of iodinated
contrast media that are not indicated for
intrathecal use. These serious adverse
reactions include: death, convulsions,
cerebral hemorrhage, coma, paralysis,
arachnoiditis, acute renal failure, cardiac
arrest, seizures, rhabdomyolysis,
hyperthermia, and brain edema. Special
attention must be given to insure that
this drug product is not inadvertently
administered intrathecally. The possibility exists for inadvertent
administration into the intrathecal space
during epidural administrations.
Therefore, epidural administration
procedures, such as pain management
catheter placement, should not be
performed with use of this product.<br/>General: Apart from the possible adverse effects
of diatrizoate meglumine, the hazards of
the performance of a retrograde
genitourinary procedure exist. These
include such complications as
hematuria, perforation of the ureter or
bladder, introduction of infection into
the genitourinary tract, and oliguria or
anuria.
|
dailymed-instance:represent... | |
dailymed-instance:routeOfAd... | |
dailymed-instance:name |
Reno-30
|